PharmaCyte Biotech, Inc. bought QCLS
November 14, 2025 · Form 4 insider transaction
PharmaCyte Biotech, Inc. bought 889,865 shares of Q/C Technologies, Inc., a transaction worth N/A. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
889,865
Price
N/A
Total value
N/A
InsiderPharmaCyte Biotech, Inc.
Role—
SecurityWarrants
Transaction codeP: Open-market purchase
Transaction dateNovember 14, 2025
Filing dateNovember 18, 2025
Shares owned after889,865
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.